Results 131 to 140 of about 49,741 (289)

Tumor Endothelial Cells Induce M2 Macrophage Polarization via IL‐4, Enhancing Tumor Growth in Hepatocellular Carcinoma

open access: yesCancer Science, EarlyView.
Tumor endothelial cells (TECs) promote the polarization of macrophages to M2 subtype by secreting IL‐4. Downregulation of IL‐4 in TECs suppressed M2 polarization and tumor progression. A high abundance of both TECs and M2 macrophages in HCC specimens is associated with poor prognosis.
Daijiro Matoba   +17 more
wiley   +1 more source

FAM20C Modulates Neuronal Differentiation in Hypoxic–Ischemic Brain Damage via KAP1 Phosphorylation and LINE1 RNA m6A‐Dependent H3K9me3 Regulation

open access: yesCell Proliferation, EarlyView.
FAM20C regulates the composition of the YTHDC1‐NCL‐KAP1‐LINE1 RNAs complex, thereby affecting neuronal differentiation in hypoxic–ischemic brain damage (HIBD). ABSTRACT Neurodevelopmental impairment due to hypoxic–ischemic brain damage (HIBD) lacks effective biomarkers and therapeutic targets.
Chen‐xi Feng   +8 more
wiley   +1 more source

A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Cardiometabolic disease (CMD) is associated with an increased risk of metabolic dysfunction‐associated steatohepatitis (MASH). Most patients develop MASH in association with type 2 diabetes and obesity. Optimal disease management requires effective multidisciplinary collaboration between primary care physicians and specialists from different ...
James Kim   +5 more
wiley   +1 more source

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major global cause of liver disease, driven by obesity and insulin resistance (IR). IR promotes hepatic lipid accumulation, inflammation and mitochondrial dysfunction, accelerating MASLD progression to fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
Alfredo Caturano   +15 more
wiley   +1 more source

ASSOCIATION OF SERUM ALPHA FETOPROTEIN (AFP) LEVELS WITH SIZE OF HEPATOCELLULAR CARSINOMA

open access: yesPakistan Armed Forces Medical Journal, 2019
Objective: To determine the association between high levels of serum Alpha Fetoprotein (AFP) and tumor size in hepatocellular carcinoma (HCC). Study Design: Cross-sectional analytical study. Place and Duration of Study: Department of Gastroenterology and
Khawar Sahbbir   +6 more
doaj  

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma

open access: yesHepatology Research, EarlyView.
ABSTRACT Background and Aims The relationship between oxidative stress (OS) and hepatocellular carcinoma (HCC) is well known, influencing both, hepatocarcinogenesis and subsequent tumor progression. Less understood is its potential role in antitumor defense mechanisms.
Víctor Merino   +7 more
wiley   +1 more source

Αlpha-fetoprotein Producing Gastric Cancer with Yolk Sac Component: Two Rare Case Reports

open access: yesMiddle East Journal of Cancer, 2016
Alpha-fetoprotein producing gastric cancer accounts for less than 10% of the gastric adenocarcinomas. Different histologic subtypes may exist, the least common of which is yolk sac morphology.
Bita Geramizadeh   +2 more
doaj  

A primary lung carcinoma producing alpha-fetoprotein, carcinoembryonic antigen, and human chorionic gonadotropin. Immunohistochemical and biochemical studies [PDF]

open access: bronze, 1987
Tomohiro Yoshimoto   +8 more
openalex   +1 more source

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study

open access: yesHepatology Research, EarlyView.
ABSTRACT Aim This study is aimed to evaluate the safety and outcomes of surgical resection in patients with hepatocellular carcinoma (HCC) treated with systemic therapy, address the therapeutic benefit, and identify candidates for surgery after systemic treatment.
Takamichi Ishii   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy